| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.0088 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |